HYCAMTIN 0.25 mg hard capsules
Authorisation EU/1/96/027/006 · Sandoz Pharmaceuticals d.d.
- Licence holder
- Sandoz Pharmaceuticals d.d. (all products →)
- Active substance
- Topotecan hydrochloride
- Clinical trials
- 51 clinical trials →
- Dosage form
- Capsule, hard
- Route of administration
- Oral use
- ATC code
- L01CE01
- First authorised
- 18/03/2008
- Prescription status
- Product subject to prescription which may not be renewed (A)
- Supply
- Supply through pharmacies only
- Legal basis
- Full application (Article 8(3) of Directive No 2001/83/EC)
Topotecan hydrochloride: supply and approvals
6 authorised products on the HPRA list contain Topotecan hydrochloride. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- Hycamtin: Shortage resolved, first published 7 Nov 2023
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 20 Nov 2026)
- Germany (BfArM)
- No entry in the BfArM supply notices (checked 20 Nov 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
About this licence
Centralised EU authorisation. This product holds an EU-wide marketing authorisation granted by the European Commission after assessment by the European Medicines Agency, valid in every EU country. Its EU product number is 027. It has been authorised for 18 years (since 18 March 2008). The HPRA list does not say whether it is on sale.
Other medicines with Topotecan hydrochloride in Ireland
5 other products on the HPRA list contain Topotecan hydrochloride, from 2 licence holders; 0 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| HYCAMTIN 1 mg hard capsules | Sandoz Pharmaceuticals d.d. | Centralised EU authorisation | Not stated |
| HYCAMTIN 4 mg powder for concentrate for solution for infusion | Sandoz Pharmaceuticals d.d. | Centralised EU authorisation | Not stated |
| Hycamtin 4 mg powder for concentrate for solution for infusion | Sandoz Pharmaceuticals d.d. | Centralised EU authorisation | Not stated |
| Potactasol 1 mg powder for concentrate for solution for infusion | Actavis Group hf | Centralised EU authorisation | Not stated |
| Potactasol 4 mg powder for concentrate for solution for infusion | Actavis Group hf | Centralised EU authorisation | Not stated |
The licence holder
Sandoz Pharmaceuticals d.d. holds 29 products on the HPRA list, with 11 different active substances; 19 of the products are marked as marketed.
This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.
How this page is built
The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.
- HPRA Authorised Medicines List (open data) ↗ Licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status for this product
This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 21 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.